Synopsis: Shares surged up to 7% after reporting the strongest-ever quarterly performance, with topline rising 16% YoY and earnings jumping 92%. UVG stood at 30.2%, while focus and younger brands grew over 25%. Distribution expanded to 2.7 lakh outlets, supporting...
Synopsis: Jewellery stock gained attention after strong Q3FY26 performance, with earnings surging sharply year-on-year. The company expanded to 196 showrooms across 18 states, adding 21 stores in nine months. Despite gold prices jumping 63%, ATV rose to ₹93,000,...
Synopsis: Axis Direct has initiated a Buy with a ₹1,540 target, implying nearly 34% upside from ₹1,150. Margins improved to ₹8.3/scm despite higher Henry Hub prices, while volumes grew 7% YoY to 4.62 mmscmd. Management guides double-digit growth ahead with ₹1,200...
Synopsis: Banking stocks gained attention after the RBI approved up to 9.95% stake acquisition by a major AMC and its group entities in multiple private lenders. The approvals, dated February 10–11, 2026, are valid for one year and subject to regulatory compliance,...
Synopsis: Shares fell around 6% after 71.7 million shares, nearly 3% equity, became eligible for trading post lock-in expiry. Despite strong user growth to 4.37 million and a treasury of ₹50,544 million, increased free float weighed on sentiment. The shares of the...
Synopsis: Healthcare stock fell up to 6.3% after mixed Q3FY26 results, with shares near ₹171 and market cap around ₹1,850 crore. EBITDA declined to ₹375 million, while net debt stood at ₹4,086 million. Occupancy dropped to 44%, and surgeries fell 8.5%, reflecting...
Synopsis: The infrastructure EPC player maintains a robust Rs 41,000 crore order book, up 49% since 2021, with a strong presence across T&D, Civil, and Transportation. Operating margins improved to 7–8%, while borrowings stood at Rs 6,806 crore....
Synopsis:- Ace investor portfolio review highlights four stocks trading below industry P/E averages, ranging from 12.9x to 61.5x versus higher sector benchmarks. Market caps span ₹333 crore to ₹3,300 crore, with shareholdings between 2% and 4.33%. While some show...
Synopsis:- ICICI Direct maintains a Buy with ₹1,310 target, implying 38% upside. Q3 saw 16.7% YoY growth, led by 49% surge in sterile injectables. Radiopharma contributes 45% of the mix, with 81% exposure to the US. Vision 2030 targets doubling scale and achieving...
